Glucophage

Glucophage is a prescription medication whose active ingredient is metformin hydrochloride, a biguanide antidiabetic agent. While the specific dosage strength and dosage form are not detailed in this entry, Glucophage is administered orally and is marketed in the European Union. It belongs to the therapeutic class of antidiabetic drugs and is primarily used to improve blood glucose control in adults with type 2 diabetes mellitus.

Glucophage is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus, often as part of a comprehensive treatment plan that includes diet and exercise.

- As monotherapy in patients newly diagnosed with type 2 diabetes. - In combination with other oral antidiabetic agents when glycemic control is insufficient. - As adjunct to insulin therapy for patients requiring additional glucose lowering. - To improve insulin sensitivity and reduce hepatic glucose output. - For patients with overweight or obesity where weight-neutral therapy is desired.

The safety profile of Glucophage includes a range of adverse effects that vary in frequency and severity.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Decreased appetite or mild weight loss. - Vitamin B12 deficiency with long‑term use. - Headache or dizziness. - Fatigue or malaise.

Serious: - Lactic acidosis, a rare but potentially life‑threatening condition. - Severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Glucophage, healthcare providers assess several clinical factors to minimize risks and ensure appropriate use.

- Evaluate renal function; contraindicated in severe renal impairment. - Review hepatic status, as liver disease may increase lactic acidosis risk. - Assess for conditions that predispose to hypoxia, such as heart failure or recent myocardial infarction. - Use caution in elderly patients due to altered drug clearance. - Monitor vitamin B12 levels during long‑term therapy. - Discontinue before any radiographic studies using iodinated contrast agents.

Glucophage can interact with other medicines, affecting its efficacy or safety.

Avoid: - Iodinated contrast media used for imaging studies. - Cimetidine, which may increase metformin plasma concentrations. - Alcohol excess, which can raise the risk of lactic acidosis.

Use with caution: - Certain diuretics that may impair renal function. - ACE inhibitors or ARBs, especially in patients with renal insufficiency. - Beta‑blockers, as they may mask hypoglycemia symptoms.